Optimized Self-Nanoemulsifying Delivery System Based on Plant-Derived Oil Augments Alpha-Lipoic Acid Protective Effects Against Experimentally Induced Gastric Lesions
- PMID: 33867893
- PMCID: PMC8020240
- DOI: 10.1177/15593258211001259
Optimized Self-Nanoemulsifying Delivery System Based on Plant-Derived Oil Augments Alpha-Lipoic Acid Protective Effects Against Experimentally Induced Gastric Lesions
Abstract
Peptic ulcer disease is an injury of the alimentary tract that leads to a mucosal defect reaching the submucosa. Alpha-lipoic acid (ALA), a natural potent antioxidant, has been known as a gastroprotective drug yet its low bioavailability may restrict its therapeutic efficacy. This study aimed to formulate and optimize ALA using a self-nanoemulsifying drug delivery system (SNEDDS) with a size of nano-range, enhancing its absorption and augmenting its gastric ulcer protection efficacy. Three SNEDDS components were selected as the design factors: the concentrations of the pumpkin oil (X1, 10-30%), the surfactant tween 80 (X2, 20-50%), and the co-surfactant polyethylene glycol 200 (X3, 30-60%). The experimental design for the proposed mixture produced 16 formulations with varying ALA-SNEDDS formulation component percentages. The optimized ALA-SNEDDS formula was investigated for gastric ulcer protective effects by evaluating the ulcer index and by the determination of gastric mucosa oxidative stress parameters. Results revealed that optimized ALA-SNEDDS achieved significant improvement in gastric ulcer index in comparison with raw ALA. Histopathological findings confirmed the protective effect of the formulated optimized ALASNEDDS in comparison with raw ALA. These findings suggest that formulation of ALA in SNEDDS form would be more effective in gastric ulcer protection compared to pure ALA.
Keywords: COX2; alpha-lipoic acid; gastritis; indomethacin; nanotechnology; stomatitis.
© The Author(s) 2021.
Conflict of interest statement
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
References
-
- Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am. 2002;86(6):1447–1466, viii. doi:10.1016/s0025-7125(02)00083-4 - PubMed
-
- Lee A. Animal models of gastroduodenal ulcer disease. Baillieres Best Pract Res Clin Gastroenterol. 2000;14(1):75–96. doi:10.1053/bega.2000.0060 - PubMed
-
- Lucas S. The pharmacology of indomethacin. Headache. 2016;56(2):436–446. doi:10.1111/head.12769 - PubMed
-
- Albayrak F, Odabasoglu F, Halici Z, et al. The role of erythropoietin in the protection of gastric mucosa from indometacin-induced gastric injury and its relationship with oxidant and antioxidant parameters in rats. J Pharm Pharmacol. 2010;62(1):85–90. doi:10.1211/jpp.62.01.0009 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
